As of the end of the quarter Fny Partners Fund Lp had acquired a total of 10 shares growing its position 66.7%.
While Clovis shares surged on news of the ARIEL-3 data, the biotech disclosed in a securities filing that it had entered into a settlement agreement to resolve a lawsuit alleging the company misled investors about the potential of another cancer drug called rociletinib. Stock institutional ownership is 84.30% while insider ownership includes 0.50%. State Street Corp now owns 2,141,663 shares of the biopharmaceutical company's stock worth $95,131,000 after buying an additional 1,035,917 shares during the period.
A look at some of the inputs to technical analysis model shows how Clovis Oncology, Inc. current price compares to its recent moving averages. The top-line data reported this morning clearly reflect the best-case outcome for CLVS highlighted in our prior report indicating that efficacy of the three leading PARP inhibitors looks very comparable and we expect shares to trade up significantly. The stock of Clovis Oncology Inc (NASDAQ:CLVS) has "Overweight" rating given on Wednesday, May 17 by JP Morgan. Norges Bank purchased a new stake in Clovis Oncology during the fourth quarter valued at approximately $13,155,000. On average, equities analysts predict that Clovis Oncology, Inc. will post ($4.95) EPS for the current fiscal year.
At the time of writing, the stock was trading at $84.50. Perceptive Advsr Ltd Liability has invested 0.53% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS). The biopharmaceutical company reported ($1.33) EPS for the quarter, beating the consensus estimate of ($1.43) by $0.10. The business had revenue of $7.05 million during the quarter, compared to analysts' expectations of $6.04 million. Artal Grp Sa has invested 0.05% in Clovis Oncology Inc (NASDAQ:CLVS).
Shares of Clovis Oncology, Inc. RBC Capital Markets maintained the shares of CVS in report on Wednesday, August 5 with "Outperform" rating. If you are reading this story on another website, it was copied illegally and reposted in violation of U.S. and worldwide copyright & trademark legislation. The correct version of this story can be viewed at https://www.chaffeybreeze.com/2017/06/18/clovis-oncology-inc-clvs-stake-decreased-by-state-board-of-administration-of-florida-retirement-system-updated.html.
A number of research firms recently weighed in on CLVS. Consonance Mgmt L P, New York-based fund reported 2.73 million shares. Leerink Swann began coverage on Clovis Oncology in a report on Tuesday, June 13th.
Shares of Clovis closed Friday at $59.97, with a consensus analyst price target of $71.17 and a 52-week range of $11.57 to $74.94. The company now has an average rating of "Buy" and an average target price of $63.33. After $-1.33 actual earnings per share reported by Clovis Oncology Inc for the previous quarter, Wall Street now forecasts 3.01% negative EPS growth. Federated Invsts Inc Pa holds 0% in Clovis Oncology Inc (NASDAQ:CLVS) or 14,423 shares. 2,700 are held by Pnc Fincl Group Inc Incorporated Inc. Morgan Stanley raised their price objective on Clovis Oncology from $68.00 to $72.00 and gave the company an overweight rating in a research note on Thursday, February 23rd. Tesarostock fell in Monday trading, while shares of Clovis rose by more than 40% in value. About 5.92M shares traded or 279.49% up from the average. Over the last quarter, insiders have sold 9,000 shares of company stock valued at $495,690.
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other worldwide markets.